193 related articles for article (PubMed ID: 37756519)
1. Impaired fibrinolysis and increased clot strength are potential risk factors for thrombosis in lymphoma.
Bønløkke ST; Fenger-Eriksen C; Ommen HB; Hvas AM
Blood Adv; 2023 Nov; 7(22):7056-7066. PubMed ID: 37756519
[TBL] [Abstract][Full Text] [Related]
2. Increased urokinase and consumption of α
Longstaff C; Locke M
J Thromb Haemost; 2019 Jan; 17(1):195-205. PubMed ID: 30451372
[TBL] [Abstract][Full Text] [Related]
3. Elevated tissue plasminogen activator and reduced plasminogen activator inhibitor promote hyperfibrinolysis in trauma patients.
Cardenas JC; Matijevic N; Baer LA; Holcomb JB; Cotton BA; Wade CE
Shock; 2014 Jun; 41(6):514-21. PubMed ID: 24667610
[TBL] [Abstract][Full Text] [Related]
4. Regulation by alpha 2-antiplasmin and fibrin of the activation of plasminogen with recombinant staphylokinase in plasma.
Silence K; Collen D; Lijnen HR
Blood; 1993 Aug; 82(4):1175-83. PubMed ID: 7688990
[TBL] [Abstract][Full Text] [Related]
5. An analysis of mechanisms underlying the antifibrinolytic properties of radiographic contrast agents.
Farrehi PM; Zhu Y; Fay WP
J Thromb Thrombolysis; 2001 Dec; 12(3):273-81. PubMed ID: 11981110
[TBL] [Abstract][Full Text] [Related]
6. Excessive fibrinolysis in suspected amyloidosis: demonstration of plasmin-alpha 2-plasmin inhibitor complex and von Willebrand factor fragment in plasma.
Takahashi H; Koike T; Yoshida N; Kitahara O; Hanano M; Shibata A; Aoki N
Am J Hematol; 1986 Oct; 23(2):153-66. PubMed ID: 2944378
[TBL] [Abstract][Full Text] [Related]
7. In vitro fibrinolysis after adding low doses of plasminogen activators and plasmin generation with and without oxidative inactivation of plasmin inhibitors in newborns and adults.
Ries M; Klinge J; Rauch R; Trusen B; Zenker M; Keuper H; Harms D
J Pediatr Hematol Oncol; 1996 Nov; 18(4):346-51. PubMed ID: 8888740
[TBL] [Abstract][Full Text] [Related]
8. Tranexamic acid rapidly inhibits fibrinolysis, yet transiently enhances plasmin generation in vivo.
Draxler DF; Zahra S; Goncalves I; Tran H; Hanafi G; Ho H; Keragala CB; Ilich A; Key NS; Myles PS; Medcalf RL
Blood Coagul Fibrinolysis; 2021 Apr; 32(3):172-179. PubMed ID: 33443933
[TBL] [Abstract][Full Text] [Related]
9. Effects of kringles derived from human plasminogen on fibrinolysis in vitro.
Sugiyama N; Iwamoto M; Abiko Y
Thromb Res; 1987 Aug; 47(4):459-68. PubMed ID: 2821651
[TBL] [Abstract][Full Text] [Related]
10. Altered Fibrinolysis in Hematological Malignances.
Bønløkke ST; Ommen HB; Hvas AM
Semin Thromb Hemost; 2021 Jul; 47(5):569-580. PubMed ID: 34058766
[TBL] [Abstract][Full Text] [Related]
11. A direct oral anticoagulant edoxaban accelerated fibrinolysis via enhancement of plasmin generation in human plasma: dependent on thrombin-activatable fibrinolysis inhibitor.
Morishima Y; Honda Y
J Thromb Thrombolysis; 2019 Jul; 48(1):103-110. PubMed ID: 30972711
[TBL] [Abstract][Full Text] [Related]
12. Fibrinolysis in patients with chemotherapy-induced thrombocytopenia and the effect of platelet transfusion.
Heubel-Moenen FCJI; Henskens YMC; Verhezen PWM; Wetzels RJH; Schouten HC; Beckers EAM
J Thromb Haemost; 2019 Jul; 17(7):1073-1084. PubMed ID: 31033178
[TBL] [Abstract][Full Text] [Related]
13. Compaction of fibrin clots reveals the antifibrinolytic effect of factor XIII.
Rijken DC; Abdul S; Malfliet JJ; Leebeek FW; Uitte de Willige S
J Thromb Haemost; 2016 Jul; 14(7):1453-61. PubMed ID: 27148673
[TBL] [Abstract][Full Text] [Related]
14. A shift in balance between profibrinolytic and antifibrinolytic factors causes enhanced fibrinolysis in cirrhosis.
Leebeek FW; Kluft C; Knot EA; de Maat MP; Wilson JH
Gastroenterology; 1991 Nov; 101(5):1382-90. PubMed ID: 1718809
[TBL] [Abstract][Full Text] [Related]
15. Tranexamic acid mediates proinflammatory and anti-inflammatory signaling via complement C5a regulation in a plasminogen activator-dependent manner.
Barrett CD; Moore HB; Kong YW; Chapman MP; Sriram G; Lim D; Moore EE; Yaffe MB
J Trauma Acute Care Surg; 2019 Jan; 86(1):101-107. PubMed ID: 30575685
[TBL] [Abstract][Full Text] [Related]
16. [Measurements of plasmin-alpha 2 plasmin inhibitor complex and FDP.D dimer levels in the fibrinolytic therapy of acute pulmonary thromboembolism].
Yamasawa F; Hasegawa N; Asano K; Sayama K; Fujita H; Urano T; Aoki T; Ishizaka A; Kanazawa M; Kawashiro T
Kokyu To Junkan; 1992 Jul; 40(7):685-90. PubMed ID: 1387724
[TBL] [Abstract][Full Text] [Related]
17. The antifibrinolytic effects of carbon monoxide-releasing molecule-2 are fibrin and alpha2-antiplasmin dependent.
Nielsen VG
Blood Coagul Fibrinolysis; 2010 Sep; 21(6):584-7. PubMed ID: 20683324
[TBL] [Abstract][Full Text] [Related]
18. Tissue plasminogen activator (tPA) inhibits plasmin degradation of fibrin. A mechanism that slows tPA-mediated fibrinolysis but does not require alpha 2-antiplasmin or leakage of intrinsic plasminogen.
Wu JH; Diamond SL
J Clin Invest; 1995 Jun; 95(6):2483-90. PubMed ID: 7769094
[TBL] [Abstract][Full Text] [Related]
19. Fluorogenic fibrinogen and fibrin facilitate macromolecular assembly and dynamic assay of picomolar levels of plasminogen activators under well mixed conditions.
Wu JH; Diamond SL
Thromb Haemost; 1995 Aug; 74(2):711-7. PubMed ID: 8585011
[TBL] [Abstract][Full Text] [Related]
20. Plasma from patients with vaccine-induced immune thrombotic thrombocytopenia displays increased fibrinolytic potential and enhances tissue-type plasminogen activator but not urokinase-mediated plasminogen activation.
Keragala CB; McFadyen JD; Ho H; McCutcheon FM; Liu Z; Stevens H; Monagle P; Chunilal S; Medcalf RL; Tran H
J Thromb Haemost; 2024 Mar; 22(3):785-793. PubMed ID: 37944898
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
